Dr Gil Morgan from OncoAlert gives his oncology highlights from social media for July 28th to August 3rd, 2023.
He begins by highlighting the FDA approval of dostarlimab for primary advanced or recurrent endometrial cancer.
Dr Morgan also covers results from the KEYNOTE-756 trial with news that the study has met the primary endpoint for pathological complete response rate in high-risk, early stage, ER positive, HER-2 negative breast cancer.
He also invites colleagues to the 'Multidisciplinary Perspectives in Breast Cancer' conference taking place on October 6th.
Follow Dr Morgan on twitter: @OncoAlert
Follow ecancer on twitter: @ecancer